Symbols

PRME

Prime Medicine·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PRME

Prime Medicine, Inc.

A biotechnology company that focused on cure genetic disorders by deploying Prime Editing technology

Industry

Biological Technology

Established Date

Listing Date

10/20/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

146

Fiscal Year Ends

12-31

Website

www.primemedicine.com

Security Type

Common stock

Office address

60 First Street, Cambridge, MA 02141

Business

Introduction

Prime Medicine, Inc., was incorporated in Delaware in September 2019. The company is a biotechnology company dedicated to delivering a new class of differentiated one-time therapeutic gene therapies — Prime Editors, which address the broadest spectrum of diseases by deploying Prime Editing technology.

Company Financials

EPS

PRME has released its 2025 Q4 earnings. EPS was reported at -0.24, versus the expected -0.25, beating expectations. The chart below visualizes how PRME has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PRME has released its 2025 Q4 earnings report, with revenue of 838.00K, reflecting a YoY change of -61.61%, and net profit of -46.08M, showing a YoY change of -9.00%. The Sankey diagram below clearly presents PRME's revenue sources and cost distribution.